Vaccines remain one of the most effective ways to prevent COVID-19 infections and serious disease. With vaccination rates around the globe still increasing, recent estimates suggest that the majority of adults could be vaccinated against COVID-19 by mid-2022.1 However, current vaccines may not optimally protect against new variants and protection from both natural and vaccine immunity may diminish over time.2

On February 23rd 2022, we announced that we intend to submit data from both our booster and Phase 3 efficacy trials as the basis for regulatory applications for a COVID-19 vaccine. 

Our Adjuvanted Recombinant Protein-based Vaccine Candidate

The vaccine antigen is the spike protein that will stimulate the immune system to produce antibodies against the virus
 

OUR PHASE 2 TRIAL FOR THE RECOMBINANT BOOSTER VACCINE CANDIDATE
OUR PHASE 3 TRIAL FOR THE RECOMBINANT VACCINE CANDIDATE

Our Commitment to Fighting COVID-19

Throughout the ongoing pandemic, we have joined forces to fight COVID-19
 

Frequently Asked Questions (FAQ)

FIND OUT MORE ABOUT SANOFI'S VACCINES

Recent COVID-19 Press Releases

More on Vaccines

R&D Pipeline

mRNA Technology: Vaccines and Beyond

Vaccines: Innovation for Disease Prevention and Control

References

  1. GAVI. Covax Global Supply Forecast. Available at: https://www.gavi.org/sites/default/files/covid/covax/COVAX%20Supply%20Forecast.pdf. Last accessed October 2021.
  2. Nature. COVID vaccines protect against Delta, but their effectiveness wanes. 19 August 2021. Available at: https://www.nature.com/articles/d41586-021-02261-8. Last accessed October 2021

MAT-GLB-2101926 02/2022 v3.0